Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03274622 · ClinicalTrials.gov registry record · NA
Efficacy of IMPACT in Infant Siblings of Children With ASD
A NA study of Autism Spectrum Disorder, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
- 2
- Study locations
NCT03274622: Completed NA study of Autism Spectrum Disorder, sponsored by Vanderbilt University.
NCT03274622 is a NA study of Autism Spectrum Disorder that has completed, run by Vanderbilt University. The registered enrollment target is 97 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (28% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03274622, a NA study of Autism Spectrum Disorder, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
- 2
- Study locations
Study Summary
Over a 5 year period infant and baby siblings of children with autism spectrum disorders (ASD) will be recruited to this study and will be randomized into 2 groups. Parents of the intervention group will receive 12 weeks of coaching in how to implement this intervention. Parents randomized to the control group will not receive intervention coaching. Both groups will attend a series of clinic appointments for data collection that occur at 3 month intervals over a 9 month period.
Primary Outcome
weighted frequency of intentional communication from the Communication and Symbolic Behavior Scale, high is good range is 0 - 400
Conditions Studied
Interventions
- BEHAVIORAL Impact Parent Training
- BEHAVIORAL No Impact
Study Locations (2)
Tennessee
- Vanderbilt University - Nashville
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2016-02-16 |
| Est. Completion | 2019-08-30 |
| Phase | NA |
What the finished NCT03274622 record still lists
NCT03274622 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 2 interventions - of which Impact Parent Training is the first listed.
NCT03274622 reports a single indexed study location in Tennessee, Washington.
Frequently Asked Questions
What is clinical trial NCT03274622 about?
NCT03274622 is a clinical study titled "Efficacy of IMPACT in Infant Siblings of Children With ASD". Over a 5 year period infant and baby siblings of children with autism spectrum disorders (ASD) will be recruited to this study and will be randomized into 2 groups. Parents of the intervention group will receive 12 weeks of coaching in how to implement this intervention. Parents randomized to the co...
What is the current status of trial NCT03274622?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2016-02-16. Estimated completion is 2019-08-30.
What conditions does trial NCT03274622 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
What interventions are being tested in trial NCT03274622?
The interventions under investigation include: Impact Parent Training (BEHAVIORAL), No Impact (BEHAVIORAL).
Who is sponsoring clinical trial NCT03274622?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03274622 being conducted?
This trial has 2 study locations across Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03274622's enrollment target sits among peer trials
97 79th of 224 higher than 146 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Milieu Teaching-AV (MT-AV Pilot)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI